Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
The therapeutic efficacies of disodium ticarcillin, tobramycin sulfate, and N-formimidoyl thienamycin (MK0787) were compared in guinea pigs with experimentally induced Pseudomonas aeruginosa pneumonia. Survival rates were 35% for ticarcillin, 80% for tobramycin, and 75% for N-formimidoyl thienamycin. Numbers of viable Pseudomonas organisms in lungs approximately 3 h after the first dose of drug were nearly 10-fold fewer in tobramycin- or N-formimidoyl thienamycin-treated animals than in ticarcillin-treated animals. Our data suggest that N-formimidoyl thienamycin may have therapeutic efficacy against respiratory infections with P. aeruginosa equivalent to that of tobramycin.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006168:Guinea Pigs; D015378:Imipenem; D008297:Male; D010406:Penicillins / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013845:Thienamycins / Q000627:therapeutic use*; D013982:Ticarcillin / Q000627:therapeutic use*; D014031:Tobramycin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D010406:Penicillins; D013845:Thienamycins; D015378:Imipenem; D013982:Ticarcillin; D014031:Tobramycin